What is the appropriate first‑line medication choice and dosing for a 26‑year‑old woman with attention‑deficit/hyperactivity disorder, considering contraindications?

First-Line Medication Selection for a 26-Year-Old Woman with ADHD

Start with a long-acting stimulant—either lisdexamfetamine (Vyvanse) 20–30 mg once daily or methylphenidate extended-release (Concerta) 18 mg once daily—because stimulants achieve 70–80% response rates and produce the largest effect sizes (≈1.0) of any ADHD medication class. 1, 2

Why Stimulants Are First-Line

• Amphetamine-based stimulants (lisdexamfetamine, mixed amphetamine salts XR) are preferred for adults based on comparative efficacy studies, with response rates of 70–80% and superior effect sizes compared to methylphenidate in head-to-head trials. 1, 2
• Methylphenidate remains equally appropriate as first-line therapy, particularly if you prefer to start with a medication that has slightly lower cardiovascular effects (average increases of 1–2 bpm heart rate and 1–4 mmHg blood pressure versus amphetamines). 3, 2
• Stimulants work within days, allowing rapid assessment of efficacy, whereas non-stimulants require 2–12 weeks to reach full therapeutic effect. 1, 3

Specific Dosing Recommendations

Lisdexamfetamine (Vyvanse)

• Start at 20–30 mg once daily in the morning. 1, 3
• Increase by 10 mg each week based on symptom response and tolerability. 1
• Maximum dose is 70 mg daily. 1, 3

Methylphenidate Extended-Release (Concerta)

• Start at 18 mg once daily in the morning (equivalent to methylphenidate 5 mg three times daily). 1, 4
• Increase by 18 mg each week until optimal symptom control is achieved. 1, 4
• Maximum dose is 54–72 mg daily for adults. 1, 4

Mixed Amphetamine Salts XR (Adderall XR)

• Start at 10 mg once daily in the morning. 1, 3
• Increase by 5 mg each week. 1
• Maximum dose is 50 mg daily (though some patients may require up to 0.9 mg/kg or 65 mg with clear documentation that lower doses were insufficient). 1

Baseline Assessment Before Initiating Stimulants

• Obtain blood pressure and pulse at baseline, as stimulants typically raise systolic/diastolic pressure by 3–5 mmHg and heart rate by 5–10 bpm. 1, 3
• Screen for personal and family cardiac history, specifically asking about sudden cardiac death in relatives younger than 50 years, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, Long QT syndrome, unexplained syncope, chest pain, or palpitations. 1, 3
• Assess for substance use disorder, as active stimulant abuse is an absolute contraindication to prescribing controlled stimulants. 1, 3
• Screen for comorbid anxiety, depression, or bipolar disorder using validated tools, as these conditions influence treatment sequencing. 1, 3

Absolute Contraindications to Stimulants

• Symptomatic cardiovascular disease or uncontrolled hypertension 1, 3
• Active psychosis or mania 1
• Concurrent use of MAO inhibitors (or within 14 days of stopping an MAOI) due to risk of hypertensive crisis 1
• Active stimulant use disorder 1, 3
• Known hypersensitivity to amphetamines or methylphenidate 1

When to Use Non-Stimulants as First-Line

Reserve non-stimulant medications (atomoxetine, guanfacine, clonidine) for patients who have failed ≥2 stimulant trials, experience intolerable stimulant side effects, or have an active substance-use disorder. 1, 3

Atomoxetine (Strattera)

• Target dose is 60–100 mg daily (maximum 1.4 mg/kg/day or 100 mg, whichever is lower). 1, 3
• Start at 40 mg daily, then increase after 2–4 weeks to 60 mg, then 80 mg if needed. 1
• Full therapeutic effect requires 6–12 weeks (median ≈3.7 weeks). 1, 3
• Effect size is approximately 0.7, compared to stimulants (≈1.0). 1, 3
• Provides 24-hour symptom coverage and has no abuse potential, making it useful when substance-misuse risk exists. 1, 3
• FDA black-box warning for suicidal ideation mandates baseline and regular screening. 1, 3

Extended-Release Guanfacine (Intuniv)

• Start at 1 mg once daily at bedtime. 5
• Increase by 1 mg weekly to a target of 0.05–0.12 mg/kg/day (maximum 7 mg/day). 5
• Effect size is approximately 0.7. 1, 5
• Full clinical effect is usually observed within 2–4 weeks. 1, 5
• Particularly advantageous for patients with comorbid sleep disturbances, anxiety, or tics. 1, 5
• Evening dosing is preferred due to sedative properties. 5

Extended-Release Clonidine (Kapvay)

• Start at 0.1 mg once daily at bedtime. 1
• Increase by 0.1 mg every 3–7 days based on blood-pressure response and tolerability. 1
• Effect size is approximately 0.7. 1, 5
• Clonidine carries a greater risk of rebound hypertension after abrupt discontinuation than guanfacine; therefore, it must be tapered by 0.1 mg every 3–7 days and never stopped suddenly. 5

Monitoring During Titration (First 4–6 Weeks)

• Measure blood pressure and pulse weekly during dose adjustments. 1, 3
• Obtain ADHD symptom rating scales (patient and informant) weekly. 1, 3
• Assess sleep quality and appetite changes at each visit. 1, 3
• Adjust the dose based on symptom control and tolerability. 1, 3

Maintenance Phase Monitoring

• Schedule visits monthly initially, then quarterly once stable. 1, 3
• Record blood pressure and pulse at each visit. 1, 3
• Track height and weight (less critical in adults but useful for baseline assessment). 1, 3

If First Stimulant Fails

Approximately 40% of patients respond to both methylphenidate and amphetamine, while another 40% respond to only one stimulant class. 1, 3 If an adequate response is not achieved after systematic titration of the first stimulant, switch to the alternative stimulant class (e.g., from methylphenidate to amphetamine or vice-versa) before considering non-stimulant agents. 1, 3

Common Pitfalls to Avoid

• Do not under-dose stimulants out of fear of side effects; systematic titration protocols enable roughly 70% of patients to achieve optimal response. 1, 3
• Do not assume the first dose is sufficient; most adults require titration to doses higher than the starting dose because of individual variability in response. 1, 3
• Do not base dosing on mg/kg calculations; systematic titration to the lowest effective dose that yields clinical benefit is preferred. 1, 4
• Do not switch to a different stimulant class after an inadequate trial until the patient has been titrated to the maximum tolerated dose, ensuring a fair assessment of efficacy. 1, 3
• Do not delay ADHD treatment because of comorbid mood symptoms; untreated ADHD worsens overall functional impairment and can exacerbate anxiety and depression. 1, 3

Multimodal Treatment Approach

Combine pharmacotherapy with evidence-based psychosocial interventions (e.g., CBT, psychoeducation) to achieve optimal functional outcomes. 1, 3 Cognitive Behavioral Therapy (CBT) specifically developed for ADHD is the most extensively studied psychotherapy and has been found most effective for treating ADHD, with increased effectiveness when combined with medication. 1, 3